Medical device maker Medtronic announced the start of a feasibility trial on a fully automated artificial pancreas system after medical pumps by Medtronic and Johnson & Johnson successfully sensed changes in blood sugar levels and adjusted insulin delivery in separate studies. Features in the pumps that stop insulin delivery when blood glucose levels drop too low reduced hypoglycemia events at night, when patients are least able to respond.

Full Story:
Yahoo, Bloomberg

Related Summaries